CO7250451A2 - Formulación oftálmica y método para mitigar la presbicia - Google Patents
Formulación oftálmica y método para mitigar la presbiciaInfo
- Publication number
- CO7250451A2 CO7250451A2 CO15017205A CO15017205A CO7250451A2 CO 7250451 A2 CO7250451 A2 CO 7250451A2 CO 15017205 A CO15017205 A CO 15017205A CO 15017205 A CO15017205 A CO 15017205A CO 7250451 A2 CO7250451 A2 CO 7250451A2
- Authority
- CO
- Colombia
- Prior art keywords
- ophthalmic formulation
- presbyopia
- mitigate
- mitigate presbyopia
- ophthalmic
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 201000010041 presbyopia Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 abstract 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 abstract 1
- 230000001800 adrenalinergic effect Effects 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000734 parasympathomimetic agent Substances 0.000 abstract 1
- 229960001416 pilocarpine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000004304 visual acuity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describe una formulación oftálmica que tiene una cantidad efectiva de un agente parasimpaticomimético que comprende pilocarpina, o una sal farmacéuticamente aceptable de la misma, y uno o más agonistas o antagonistas 1 adrenérgicos. La formulación oftálmica puede permitir el tratamiento de condiciones que afectan de manera adversa la agudeza visual de un paciente, incluyendo presbicia. También se describe un método para utilizar la formulación oftálmica descrita para tratar o mitigar los síntomas de la presbicia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/553,615 US10507245B2 (en) | 2012-07-19 | 2012-07-19 | Ophthalmic formulation and method for ameliorating presbyopia |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7250451A2 true CO7250451A2 (es) | 2015-04-30 |
Family
ID=48917698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO15017205A CO7250451A2 (es) | 2012-07-19 | 2015-01-28 | Formulación oftálmica y método para mitigar la presbicia |
Country Status (15)
Country | Link |
---|---|
US (2) | US10507245B2 (es) |
EP (1) | EP2874660B1 (es) |
CN (2) | CN113425715A (es) |
AR (2) | AR092860A1 (es) |
BR (1) | BR112015001158B1 (es) |
CO (1) | CO7250451A2 (es) |
DK (1) | DK2874660T3 (es) |
ES (1) | ES2719250T3 (es) |
HR (1) | HRP20190627T1 (es) |
MX (1) | MX351230B (es) |
PL (1) | PL2874660T3 (es) |
PT (1) | PT2874660T (es) |
RU (1) | RU2657514C2 (es) |
TR (1) | TR201905683T4 (es) |
WO (1) | WO2014015183A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012311239B2 (en) | 2011-09-20 | 2017-10-19 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
EP3104851A1 (en) * | 2014-02-11 | 2016-12-21 | Orasis Pharmaceuticals Ltd. | Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration |
CN104856990A (zh) * | 2015-05-07 | 2015-08-26 | 武汉武药科技有限公司 | 去氧肾上腺素酮咯酸溶液及制备方法 |
US20190000808A1 (en) * | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
CH711969A2 (it) * | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
KR102472774B1 (ko) | 2016-08-19 | 2022-11-30 | 오라시스 파마슈티칼스 엘티디. | 안과용 약학 조성물 및 이와 관련된 용도 |
US20180318319A1 (en) | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
WO2019150341A1 (en) * | 2018-02-05 | 2019-08-08 | Cellixbio Private Limited | Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof |
US20190321334A1 (en) * | 2018-04-19 | 2019-10-24 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
AU2019261598B9 (en) | 2018-04-24 | 2020-05-28 | Allergan, Inc. | Use of pilocarpine hydrochloride for the treatment of ocular conditions |
SG11202101730SA (en) * | 2018-08-21 | 2021-03-30 | Allergan Inc | The use of alpha-2-adrenergic receptor agonists for improving vision |
US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
CA3116589A1 (en) | 2018-10-26 | 2020-04-30 | Ocuphire Pharma, Inc. | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders |
US11071724B2 (en) * | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
CN114585365A (zh) * | 2019-06-10 | 2022-06-03 | 视觉治疗股份有限公司 | 在假晶状体患者中使用拟副交感神经药物单独或与一种或多种α激动剂组合以产生多焦点 |
MX2020012116A (es) * | 2020-11-12 | 2022-08-09 | Cesar Alejandro Sanchez Galeana | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia. |
CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
CN116350790A (zh) * | 2021-12-28 | 2023-06-30 | 沈阳兴齐眼药股份有限公司 | 组合物及其在制备用于治疗老花眼的药物中的用途 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474751A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
DK335086A (da) | 1985-08-05 | 1987-02-06 | Michele Testa | Kemiske sammensaetninger og farmaceutiske praeparater til topisk brug indeholdende mindst en af de kemiske sammensaetninger i en terapeutiskvirksom maengde |
US4902696A (en) * | 1987-10-08 | 1990-02-20 | Hoechst-Roussel Pharmaceuticals, Inc. | Synergistic intraocular pressure lowering combinations |
US5192780A (en) * | 1989-12-18 | 1993-03-09 | Alcon Laboratories, Inc. | Methods using antiallergics and antihistamines |
US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
ATE189772T1 (de) * | 1993-04-16 | 2000-03-15 | Wakamoto Pharma Co Ltd | Unter wärmeeinwirkung reversibel gelierende medizinische zusammensetzung auf wasserbasis |
US5677321A (en) | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
IT1306135B1 (it) * | 1999-04-26 | 2001-05-30 | Farmigea Spa | Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto. |
US20050261641A1 (en) | 2002-09-26 | 2005-11-24 | Warchol Mark P | Method for ophthalmic administration of medicament |
US20060172972A1 (en) | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
US20060177430A1 (en) | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
NZ540885A (en) | 2002-12-20 | 2009-02-28 | Chakshu Res Inc | Ophthalmic formulation for the prevention and treatment of ocular conditions |
US20060166879A1 (en) | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
US7252662B2 (en) | 2004-11-02 | 2007-08-07 | Lenticular Research Group Llc | Apparatus and processes for preventing or delaying one or more symptoms of presbyopia |
ATE439863T1 (de) | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
TNSN08110A1 (en) | 2008-03-11 | 2009-07-14 | Rekik Raouf Dr | Drug delivery to the anterior and posterior segment of the eye from drops |
TWI542338B (zh) | 2008-05-07 | 2016-07-21 | 壯生和壯生視覺關懷公司 | 用於活性劑之控制釋放的眼用裝置 |
WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
US8299079B2 (en) * | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
EP2512389B1 (en) | 2009-12-16 | 2015-09-02 | Allergan, Inc. | Intracameral devices for sustained delivery |
US20110301555A1 (en) | 2010-06-03 | 2011-12-08 | Gonzalez-Zugasti Javier P | Porous matrix drug core for lacrimal insert device |
US20120003296A1 (en) | 2010-07-01 | 2012-01-05 | Shantha Totada R | New methods of treating dry eye syndrome |
AU2012311239B2 (en) | 2011-09-20 | 2017-10-19 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
-
2012
- 2012-07-19 US US13/553,615 patent/US10507245B2/en active Active
-
2013
- 2013-07-18 CN CN202110595122.XA patent/CN113425715A/zh active Pending
- 2013-07-18 BR BR112015001158-6A patent/BR112015001158B1/pt active IP Right Grant
- 2013-07-18 PL PL13745508T patent/PL2874660T3/pl unknown
- 2013-07-18 TR TR2019/05683T patent/TR201905683T4/tr unknown
- 2013-07-18 DK DK13745508.5T patent/DK2874660T3/en active
- 2013-07-18 ES ES13745508T patent/ES2719250T3/es active Active
- 2013-07-18 EP EP13745508.5A patent/EP2874660B1/en active Active
- 2013-07-18 MX MX2015000806A patent/MX351230B/es active IP Right Grant
- 2013-07-18 CN CN201380043978.XA patent/CN104717981A/zh active Pending
- 2013-07-18 PT PT13745508T patent/PT2874660T/pt unknown
- 2013-07-18 RU RU2015102531A patent/RU2657514C2/ru active
- 2013-07-18 WO PCT/US2013/051153 patent/WO2014015183A1/en active Application Filing
- 2013-07-19 AR ARP130102572A patent/AR092860A1/es not_active Application Discontinuation
-
2015
- 2015-01-28 CO CO15017205A patent/CO7250451A2/es unknown
-
2019
- 2019-04-01 HR HRP20190627TT patent/HRP20190627T1/hr unknown
- 2019-12-03 US US16/701,602 patent/US20200237916A1/en not_active Abandoned
-
2021
- 2021-04-14 AR ARP210100987A patent/AR121843A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014015183A1 (en) | 2014-01-23 |
DK2874660T3 (en) | 2019-04-15 |
RU2657514C2 (ru) | 2018-06-14 |
PT2874660T (pt) | 2019-05-14 |
EP2874660B1 (en) | 2019-01-23 |
MX351230B (es) | 2017-10-06 |
MX2015000806A (es) | 2015-08-10 |
US10507245B2 (en) | 2019-12-17 |
TR201905683T4 (tr) | 2019-05-21 |
PL2874660T3 (pl) | 2019-07-31 |
BR112015001158A2 (pt) | 2017-06-27 |
EP2874660A1 (en) | 2015-05-27 |
HRP20190627T1 (hr) | 2019-06-14 |
RU2015102531A (ru) | 2016-09-10 |
AR121843A2 (es) | 2022-07-13 |
ES2719250T3 (es) | 2019-07-09 |
CN104717981A (zh) | 2015-06-17 |
US20140024642A1 (en) | 2014-01-23 |
US20200237916A1 (en) | 2020-07-30 |
CN113425715A (zh) | 2021-09-24 |
AR092860A1 (es) | 2015-05-06 |
BR112015001158B1 (pt) | 2020-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7250451A2 (es) | Formulación oftálmica y método para mitigar la presbicia | |
CL2014000689A1 (es) | Composicion para el tratamiento de una condicion ocular que comprende un agonista del receptor de acetilcolina muscarinico m3 y al menos otro agente activo; metodo para tratar presbicia, hipermetropia leve, astigmatismo regular, esotropia acomodativa hipermetropica y glaucoma. | |
MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
MY171920A (en) | Prevention and treatment of ocular conditions | |
BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
MY174018A (en) | Heterocyclic derivates | |
BR112014014529A2 (pt) | métodos para melhorar terapias médicas | |
CO6331301A2 (es) | Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa | |
UA114705C2 (uk) | Андрогенна композиція для лікування офтальмологічного захворювання | |
EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
BR112014028041A2 (pt) | tratamento de obesidade hipotalâmica com inibidores de metap2 | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
MX2016001865A (es) | Inhibidores biciclicos. | |
MX2018004664A (es) | Antagonistas de ep4. | |
WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
MA33991B1 (fr) | Procede de traitement des troubles de l'angiogenese oculaire ou de la fuite vasculaire | |
EA201690532A1 (ru) | Не содержащий консерванта офтальмологический фармацевтический состав | |
MD4538B1 (ro) | 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei | |
IN2014CN04809A (es) | ||
BR112015004469A2 (pt) | sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares | |
MX2022003892A (es) | Soluciones intracamerales antiinflamatorias y midriaticas para inhibicion de condiciones inflamatorias oculares postoperatorias. | |
MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
MX2018009125A (es) | Uso de antagonistas de prostaciclina para el tratamiento de la nocicepcion de la superficie ocular. | |
SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms |